Lana Pine

A similar proportion of patients sustained baseline clinical status across treatment arms.

Statistically significant higher proportions of patients with CD or UC receiving subcutaneous CT-P13 achieved clinical remission compared with placebo.

At week 54, the clinical remission rate among patients receiving originator infliximab was 92.5% compared with 100% in the biosimilar CT-P13 group.

Both the high-concentration and reference formulations of biosimilar adalimumab-adbm exhibited comparable pharmacokinetics and immunogenicity, with a similar safety profile.

Swapnil Hiremath, MD, MPH, discusses resistant hypertension, including using an evidence-based approach to management and addressing non-adherence.

At the end of the study period, the median dose of daprodustat and ESA were higher among the ESA-HR cohort when compared with the non-ESA-HR group.

During follow-up, rates of incident PAD were higher among patients with depressive symptoms compared with those without depression.

A numerically slower decline in eGFR was reported in the finerenone cohort after hospitalization for heart failure when compared with placebo.

Wei Ling Lau, MD, explains the importance of medication adherence to maximize the benefits of RAASi therapy.

Wei Ling Lau, MD, explains how to enable optimal RAASi therapy while reducing hyperkalemia risk.

Michael Shlipak, MD, MPH, explains updates to the American Heart Association's cardiovascular risk equation, which now incorporates kidney function and damage through albuminuria into its components.

Jared Hassler, MD, shares his personal journey with IgAN and discusses IgAN's clinical features and diagnosis, emphasizing the importance of routine screenings for early detection.

Patients with IgAN receiving iptacopan achieved a 38.3% reduction in proteinuria at month 9.

Findings demonstrated a slower decline in kidney function for patients treated with sparsentan or irbesartan compared with standard of care in both real-world and clinical trial settings.

Kam Kalantar-Zadeh, MD, MPH, PhD, discusses his presentation focusing on dietary challenges, potassium control, and potential solutions associated with RAASi therapy.

Kam Kalantar-Zadeh, MD, MPH, PhD, addresses the challenge healthcare providers encounter in balancing the cardiovascular advantages of RAASi therapy with the potential hazards of hyperkalemia.

Maya N. Clark-Cutaia, PhD, ACNP-BC, RN, highlights strategies to improve cardiovascular disease-related outcomes in patients with ESKD.

Areef Ishani, MD, MS, discusses the results of the Diuretic Comparison Project (DCP), which compared chlorthalidone and hydrochlorothiazide for the treatment of cardiovascular diseases.

Sylvia Rosas, MD, MSCE, discusses highlights from the National Kidney Foundation's Spring Clinical Meeting, including innovations in xenotransplantation, artificial intelligence, and the interplay between kidney, heart, and metabolic diseases.

Swapnil Hiremath, MD, MPH, explains the importance of 24-hour ambulatory blood pressure monitoring (ABPM) to rule out the possibility of white coat hypertension.

The biosimilars month in review reflects ongoing efforts to address key challenges in rheumatic disease treatment.

The current approval is based on the VOLTAIRE-HCLF clinical trial, which examined the bioavailability of high-concentration (100 mg/mL) and low-concentration (50 mg/mL) formulations of adalimumab-adbm.

The FDA approved ustekinumab-aekn for the treatment of moderate to severe plaque psoriasis and active psoriatic arthritis.

Fresenius announced the immediate availability of its tocilizumab biosimilar, tocilizumab-aazg (Tyenne), in the US.

Clinicians advocate for an at-parity approach to biosimilars, in which they, their patients, and the local market would have the freedom to choose the product that best suits their needs.

In March, FDA approved biosimilar versions of established biologic drugs for autoimmune diseases and skeletal-related events, adalimumab biosimilars demonstrated sustained efficacy and acceptance among patients, and affirmed CT-P41’s potential as an alternative treatment options in clinical practice.

Jon Martin, US Commercial Lead of Biosimilars at Organon, discusses the decision to select biosimilar adalimumab-bwwd and its potential implications on the pharmaceutical market.

The drug is the first tocilizumab biosimilar with an FDA-approved intravenous and subcutaneous formulation.

Patients who were naïve to adalimumab tended to switch to other targeted therapies, while those who had been previously treated with adalimumab were more likely to switch back to the reference product.

The primary endpoint was achieved, with biosimilar CT-P41 demonstrating comparable pharmacokinetics.